Trial Profile

A Phase 2 Clinical Study of REC-3964 in Adults for the Reduction of Recurrent Clostridioides Difficile Infection (CDI)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 19 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REC-163964 (Primary)
Indications Clostridium difficile infections
Focus Adverse reactions
Acronyms ALDER
Sponsors Recursion Pharmaceuticals

Most Recent Events

11 May 2025 Status changed from recruiting to active, no longer recruiting.
20 Nov 2024 According to a Recursion Pharmaceuticals media release, update from this study expected in Q1 2026.
22 Oct 2024 According to a Recursion Pharmaceuticals media release, the first patient has been dosed in its Phase 2 clinical trial of REC-3964, a potential first-in-class, oral small molecule and new chemical entity for the treatment of recurrent Clostridioides difficile infection.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com